Feedback / Questions
Ongentys (opicapone) - Ono Pharma, Neurocrine, BIAL
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-real-world-parkinsons-disease-patient-characteristics-from-ongentys-opicapone-open-label-study-at-ana2022-301656404.html
Oct 24, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next